title: Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data.
authors.forename: Kim
authors.initials: K
authors.lastname: Dao
authors.forename: Dana
authors.initials: D
authors.lastname: Védy
authors.forename: José
authors.initials: J
authors.lastname: Lopez
authors.forename: Olivier
authors.initials: O
authors.lastname: Staneczek
authors.forename: Thierry
authors.initials: T
authors.lastname: Buclin
authors.forename: Françoise
authors.initials: F
authors.lastname: Livio
mesh_terms: D001549:Benzamides / Q000008:administration & dosage / Q000009:adverse effects*; D057915:Drug Substitution; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000188:drug therapy*; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C498826:nilotinib